This week's episode recaps some highlights from ESMO 2025:

1. Destiny-Breast05: T-DXd > T-DM1 in persistent HER2+ disease after neoadjuvant chemo + surgery

2. Keynote-905: Neoadjuvant Enfortumab Vedotin + pembro in cisplatin-ineligible bladder cancer

3. POTOMAC: Durvalumab + BCG in non-muscle invasive bladder cancer

4. IMvigor011: ctDNA-guided adjuvant atezolizumab in bladder cancer

5. Dynamic-III: ctDNA guide de-escalation or escalation of chemotherapy in stage III colon cancer

6. HARMONi-6: an excuse to talk about ivonescimab, a bispecific antibody unlike any other currently FDA approved